The Analyst Landscape: 7 Takes On United Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on United Therapeutics (NASDAQ:UTHR) with recent ratings showing a majority bullish sentiment. The average 12-month price target has increased by 18.57% to $409.57. United Therapeutics has shown strong financial performance with a 19.85% revenue growth rate and high net margins.
October 21, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics has received mixed analyst ratings, with a majority being bullish. The average price target has increased significantly, indicating positive sentiment. The company's strong financial performance, including a 19.85% revenue growth rate and high net margins, supports this outlook.
The majority of analysts have a bullish outlook on UTHR, with an increased average price target reflecting positive sentiment. The company's strong financial metrics, such as high revenue growth and net margins, further support a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100